-
Thurs news: Novartis not joining weight loss race. Pharma marketing and climate change. Roche flu treatment trial. Cercle’s fund raise for women’s health. ICER looks at GSK COPD drugs. See more on our front page
What's the next blockbuster
- Thread starter anonymous
- Start date
-
- Tags
- None
<
Considering he, like our own fecklessleader, has never produced a good or services of value to anyone, such a statement is especially rich.
Deludium dilithio retartrate 1700 kg
Deludium dilithio retartrate 1700 kg
You might be on to something.
How about Eli Lilly Extra Pale Ale with 10 mg/serving lithium orotate? Great stuff. In some locales globally, tiny amounts of lithium are added to mineral water. May be an essential nutrient.
Oh I know we can't patent that..... sure you can, you got this!
Retain as a trade secrets and/or pursue method of making (process) + pharmaceutical compositions...evergreening-- it's a beautiful thing. Loads of billable hour$.
Retain as a trade secrets and/or pursue method of making (process) + pharmaceutical compositions...evergreening-- it's a beautiful thing. Loads of billable hour$.
Would it work to just keep doing provisionals, never let them see light of day (unless someone steals trade secrets?)
Yup, that's a strategy. Although, after a year, if you don't convert to a non provisional, you lose the original priority date of the provisional. Oddly though, you can convert the provisional to a non provisional, then convert back to a provisional (provided it hasn't published, which given the pendency backlog, will probably be at least 18 months). So you can drag it out, without anything publishing, although you will lose the original priority date.